Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
DEC2 CRISPR Activation Plasmid (m): sc-429771-ACT
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- DEC2 CRISPR Activation Plasmid (m) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- DEC2 CRISPR Activation Plasmid (m) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by DEC2 CRISPR Activation Plasmid (m) and DEC2 CRISPR Activation Plasmid (m2) target distinct regulatory regions upstream of the Bhlhe41 transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
DEC2 CRISPR Activation Plasmid (m) | sc-429771-ACT | 20 µg | $397.00 | |||
DEC2 CRISPR Activation Plasmid (m2) | sc-429771-ACT-2 | 20 µg | $397.00 |
Bhlhe41 encodes DEC2, a basic helix–loop–helix (bHLH) transcription factor that binds E-box motifs and modulates circadian gene networks and transcriptional feedback loops. In mouse, DEC2 participates in regulation of sleep–wake timing, neuronal excitability, and metabolic homeostasis by interacting with core clock components and controlling downstream rhythmic transcription. The protein also influences lineage-associated transcriptional programs, linking environmental cues to cell state transitions. Altered DEC2 activity has been associated with sleep duration phenotypes and broader dysregulation of circadian-controlled pathways relevant to neurobiology and systemic metabolism.
DEC2 CRISPR Activation Plasmid (m) provides a targeted, non-destructive approach to upregulating endogenous Bhlhe41 expression without altering the underlying DNA sequence.
DEC2 CRISPR Activation Plasmid (m) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the Bhlhe41 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the Bhlhe41 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous DEC2 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native Bhlhe41 locus and enabling the study of DEC2-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of DEC2 pathway restoration in tumor cells with silenced or reduced Bhlhe41 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.